Characterization of macrolide-resistant non-invasive pneumococci in the pre-vaccine era in Serbia

Acta Microbiologica Et Immunologica Hungarica
Suncica PopovicNatasa Opavski

Abstract

Numerous reports have confirmed that increased macrolide use in the treatment of respiratory tract infection has contributed to the emergence of antibiotic resistance worldwide. Studies have also shown that pneumococcal vaccine can reduce pneumococcal resistance. The aim of this study was to determine the prevalence of co-resistance to penicillin and other antibiotics in macrolide-resistant (MR) non-invasive pneumococcal isolates and to evaluate serotype distribution in resistant strains in the pre-vaccine era in Serbia. About 80% of MR isolates expressed the MLS phenotype with very high resistance to both erythromycin and clindamycin. A total of 132 (84.1%) MR isolates were multiresistant, i.e., they were resistant to erythromycin, penicillin, tetracycline, and trimethoprim-sulfamethoxazole. Among 157 MR pneumococci, 11 different serotypes were found. Four serotypes, 19F, 14, 6B, and 23F, accounted for 77.7% of all MR pneumococcal isolates. Among isolates with the cMLS phenotype, serotypes 19F and 14 were predominant, whereas serotype 6A was the most common among those with the M phenotype, followed by 14. In conclusion, co-resistance to macrolides and penicillin in our non-invasive pneumococcal isolates is high. The majority ...Continue Reading

References

Apr 13, 2001·JAMA : the Journal of the American Medical Association·K A RobinsonUNKNOWN Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network
Apr 3, 2001·Journal of Clinical Microbiology·M P MontanariP E Varaldo
Aug 17, 2002·Antimicrobial Agents and Chemotherapy·Roland Leclercq, Patrice Courvalin
Jul 18, 2003·The Pediatric Infectious Disease Journal·Edward O MasonUNKNOWN United States Pediatric Multicenter Pneumococcal Surveillance Study Group
May 25, 2005·Paediatric Respiratory Reviews·Talal Farha, Anne H Thomson
Jun 28, 2005·Antimicrobial Agents and Chemotherapy·Ralf René ReinertPeter Appelbaum
Sep 29, 2005·Antimicrobial Agents and Chemotherapy·Karita D AmbroseDavid S Stephens
Nov 12, 2005·The Journal of Antimicrobial Chemotherapy·David FelminghamReuben N Grüneberg
Jan 27, 2006·Microbiology·D BogaertP W M Hermans
Mar 1, 2006·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Matsuhisa InoueYoichi Hirakata
Dec 23, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M SouliH Giamarellou
Jan 31, 2007·Antimicrobial Agents and Chemotherapy·Andrea BrencianiEleonora Giovanetti
May 4, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E TammI Lutsar
Jun 2, 2007·International Journal of Antimicrobial Agents·G PoulakouUNKNOWN Hellenic Study Group for the Susceptibility of Streptococcus pneumoniae
Oct 13, 2007·International Journal of Antimicrobial Agents·Rafael CantónDavid J Farrell
Nov 13, 2008·Antimicrobial Agents and Chemotherapy·Pietro E VaraldoEleonora Giovanetti
Jan 29, 2010·Clinical and Vaccine Immunology : CVI·Didrik F VestrheimDominique A Caugant
Mar 23, 2011·International Journal of Antimicrobial Agents·Christine BleyRalf René Reinert
Apr 16, 2011·Lancet·Daniel M WeinbergerMarc Lipsitch
Sep 24, 2011·International Journal of Pediatric Otorhinolaryngology·Izabela Korona-GlowniakAnna Malm
Apr 2, 2013·Srpski arhiv za celokupno lekarstvo·Ina GajićNataša Opavski
Jun 15, 2013·Emerging Infectious Diseases·Sandra S RichterGary V Doern
Mar 25, 2014·The Lancet Infectious Diseases·Ann VersportenUNKNOWN WHO/Europe-ESAC Project Group
Aug 1, 2014·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Lena Petrova SetchanovaVanio Mitev
Nov 27, 2014·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·K Weist, L Diaz Högberg
Mar 12, 2015·Balkan Medical Journal·Leyla SirekbasanKenan Midilli
Jan 19, 2016·Current Opinion in Infectious Diseases·Catia CillónizAntoni Torres
Dec 23, 2016·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Carmen SheppardDavid M Livermore

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.